Corcept Therapeutics Stock Price, News & Analysis (NASDAQ:CORT)

$15.98 +0.42 (+2.70 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$15.98
Today's Range$15.52 - $16.32
52-Week Range$8.14 - $25.96
Volume1.45 million shs
Average Volume2.45 million shs
Market Capitalization$1.87 billion
P/E Ratio55.10
Dividend YieldN/A
Beta1.68

About Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics logoCorcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:CORT
CUSIP21835210
Phone+1-650-3273270

Debt

Debt-to-Equity RatioN/A
Current Ratio3.85%
Quick Ratio3.70%

Price-To-Earnings

Trailing P/E Ratio55.1034482758621
Forward P/E Ratio34.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$81.32 million
Price / Sales22.43
Cash Flow$0.08 per share
Price / Cash209.67
Book Value$0.37 per share
Price / Book43.19

Profitability

Trailing EPS$0.29
Net Income$8.14 million
Net Margins27.28%
Return on Equity58.17%
Return on Assets41.48%

Miscellaneous

Employees103
Outstanding Shares114,120,000

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its earnings results on Thursday, November, 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.13 by $0.02. The biotechnology company had revenue of $42.70 million for the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. The firm's revenue was up 96.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.02 earnings per share. View Corcept Therapeutics' Earnings History.

When will Corcept Therapeutics make its next earnings announcement?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Corcept Therapeutics.

Where is Corcept Therapeutics' stock going? Where will Corcept Therapeutics' stock price be in 2018?

3 brokerages have issued 12 month price targets for Corcept Therapeutics' stock. Their forecasts range from $20.00 to $30.00. On average, they expect Corcept Therapeutics' share price to reach $23.33 in the next twelve months. View Analyst Ratings for Corcept Therapeutics.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a drop in short interest in January. As of January 12th, there was short interest totalling 16,324,876 shares, a drop of 6.0% from the December 29th total of 17,362,447 shares. Based on an average daily volume of 1,633,485 shares, the days-to-cover ratio is currently 10.0 days. Approximately 16.2% of the company's shares are short sold.

Who are some of Corcept Therapeutics' key competitors?

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:

  • James N. Wilson, Independent Chairman of the Board (Age 73)
  • Joseph K. Belanoff M.D., President, Chief Executive Officer, Director (Age 59)
  • Gary Charles Robb, Chief Financial Officer, Secretary (Age 54)
  • Robert S. Fishman M.D., Chief Medical Officer (Age 55)
  • G. Leonard Baker Jr., Independent Director (Age 74)
  • Daniel Mark Bradbury, Independent Director (Age 56)
  • Renee D. Gala, Independent Director (Age 45)
  • David L. Mahoney, Independent Director (Age 62)
  • Daniel N. Swisher Jr., Independent Director (Age 54)

Who owns Corcept Therapeutics stock?

Corcept Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.99%), Ingalls & Snyder LLC (6.07%), Consonance Capital Management LP (5.06%), Renaissance Technologies LLC (4.34%), Acadian Asset Management LLC (2.17%) and Bank of New York Mellon Corp (1.35%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

Who sold Corcept Therapeutics stock? Who is selling Corcept Therapeutics stock?

Corcept Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Wells Fargo & Company MN, Globeflex Capital L P, Arrowstreet Capital Limited Partnership, TIAA CREF Investment Management LLC, Two Sigma Advisers LP, First Trust Advisors LP and Raymond James & Associates. Company insiders that have sold Corcept Therapeutics company stock in the last year include David L Mahoney, G Leonard Baker Jr, Patrick G Enright and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

Who bought Corcept Therapeutics stock? Who is buying Corcept Therapeutics stock?

Corcept Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Consonance Capital Management LP, Renaissance Technologies LLC, Old Mutual Global Investors UK Ltd., Bank of New York Mellon Corp, Fuller & Thaler Asset Management Inc., American Century Companies Inc. and Denali Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy Corcept Therapeutics stock?

Shares of Corcept Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of Corcept Therapeutics stock can currently be purchased for approximately $15.98.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.87 billion and generates $81.32 million in revenue each year. The biotechnology company earns $8.14 million in net income (profit) each year or $0.29 on an earnings per share basis. Corcept Therapeutics employs 103 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 Commonwealth Dr, MENLO PARK, CA 94025-1133, United States. The biotechnology company can be reached via phone at +1-650-3273270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (CORT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  375
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corcept Therapeutics (NASDAQ:CORT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.33$23.33$19.25$14.25
Price Target Upside: 35.19% upside23.46% upside1.85% upside17.19% upside

Corcept Therapeutics (NASDAQ:CORT) Consensus Price Target History

Price Target History for Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018Piper Jaffray CompaniesSet Price TargetBuy$30.00HighView Rating Details
2/5/2018Stifel NicolausLower Price TargetBuy$25.00 -> $20.00LowView Rating Details
7/18/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$15.00 -> $20.00LowView Rating Details
12/20/2016Janney Montgomery ScottInitiated CoverageSell$7.00N/AView Rating Details
11/2/2016FBR & CoSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Corcept Therapeutics (NASDAQ:CORT) Earnings History and Estimates Chart

Earnings by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ CORT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018$0.18N/AView Earnings Details
11/2/2017Q3 2017$0.13$0.11$41.64 million$42.70 millionViewN/AView Earnings Details
8/1/2017Q2 2017$0.08$0.10$31.37 million$35.56 millionViewN/AView Earnings Details
5/1/2017Q1 2017$0.03$0.04$25.53 million$27.60 millionViewListenView Earnings Details
3/6/2017Q4 2016$0.04$0.04$23.85 million$23.81 millionViewN/AView Earnings Details
11/1/2016Q316$0.01$0.02$21.24 million$21.70 millionViewN/AView Earnings Details
8/2/2016Q2 2016$0.01$0.01$18.33 million$19.72 millionViewN/AView Earnings Details
3/1/2016Q4 2015($0.02)$0.01$14.78 million$14.97 millionViewN/AView Earnings Details
1/28/2016Q415($0.02)$0.01$15.50 million$15.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.02)($0.01)$13.90 million$13.30 millionViewN/AView Earnings Details
8/5/2015Q215($0.04)($0.02)$11.67 million$11.96 millionViewN/AView Earnings Details
5/7/2015Q115($0.04)($0.05)$10.50 million$10.10 millionViewN/AView Earnings Details
3/4/2015Q414($0.06)($0.03)$9.10 million$9.01 millionViewN/AView Earnings Details
11/4/2014Q214($0.07)($0.05)$7.62 million$7.28 millionViewN/AView Earnings Details
8/5/2014Q2 2014($0.11)($0.06)$5.85 millionViewN/AView Earnings Details
5/7/2014Q114($0.10)($0.13)$5.01 million$4.41 millionViewN/AView Earnings Details
3/5/2014Q413($0.10)($0.11)$4.01 million$4.10 millionViewN/AView Earnings Details
1/30/2014Q4($0.12)($0.10)ViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$2.70 million$2.60 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.11)($0.10)$2.72 million$1.90 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$2.48 million$1.72 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.09)($0.09)$1.50 million$1.38 millionViewN/AView Earnings Details
10/31/2012Q3 2012($0.09)($0.08)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.11)($0.09)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.11)($0.13)ViewN/AView Earnings Details
3/5/2012Q4 2011($0.09)($0.12)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.10)($0.08)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.09)($0.11)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.11)($0.09)ViewN/AView Earnings Details
3/9/2011Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.10)($0.10)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.09)($0.09)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.08)($0.10)ViewN/AView Earnings Details
3/25/2010Q4 2009($0.11)($0.09)ViewN/AView Earnings Details
11/10/2009Q3 2009($0.10)($0.09)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.11)($0.10)ViewN/AView Earnings Details
5/11/2009Q1 2009($0.10)($0.11)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.12)($0.13)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.13)($0.11)ViewN/AView Earnings Details
8/13/2008Q2 2008($0.12)($0.09)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.15)($0.10)ViewN/AView Earnings Details
3/27/2008Q4 2007($0.10)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Corcept Therapeutics (NASDAQ:CORT) Earnings Estimates

Current Year EPS Consensus Estimate: $0.47 EPS
Next Year EPS Consensus Estimate: $0.97 EPS

Dividends

Dividend History for Corcept Therapeutics (NASDAQ:CORT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Corcept Therapeutics (NASDAQ CORT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 65.99%
Insider Trades by Quarter for Corcept Therapeutics (NASDAQ:CORT)
Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ CORT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2018Robert S FishmanInsiderSell8,000$16.60$132,800.008,000View SEC Filing  
1/8/2018Robert S FishmanInsiderSell8,000$18.67$149,360.008,000View SEC Filing  
12/8/2017Robert S FishmanInsiderSell8,000$16.72$133,760.008,000View SEC Filing  
11/13/2017G Leonard Baker JrDirectorSell30,000$17.59$527,700.00View SEC Filing  
7/19/2017David L MahoneyDirectorSell23,006$12.50$287,575.00View SEC Filing  
7/18/2017David L MahoneyDirectorSell6,091$12.50$76,137.50View SEC Filing  
7/13/2017David L MahoneyDirectorSell6,994$12.50$87,425.00View SEC Filing  
7/12/2017David L MahoneyDirectorSell6,510$12.50$81,375.00View SEC Filing  
5/4/2017Gary Charles RobbCFOBuy5,600$9.75$54,600.006,858View SEC Filing  
3/16/2017Patrick G. EnrightDirectorSell269,955$9.94$2,683,352.70View SEC Filing  
3/15/2017Patrick G EnrightDirectorSell600,000$10.15$6,090,000.00204,210View SEC Filing  
3/8/2017Patrick G EnrightDirectorSell750,000$9.75$7,312,500.00204,210View SEC Filing  
2/27/2017Patrick G EnrightDirectorSell2,500,000$8.81$22,025,000.00204,210View SEC Filing  
11/25/2016Patrick G EnrightDirectorSell36,941$9.34$345,028.94View SEC Filing  
11/21/2016Patrick G EnrightDirectorSell544,100$9.56$5,201,596.00View SEC Filing  
11/16/2016Patrick G EnrightDirectorSell174,847$9.55$1,669,788.85View SEC Filing  
11/11/2016James N WilsonDirectorSell158,812$8.51$1,351,490.12View SEC Filing  
11/11/2016Joseph K BelanoffInsiderSell500,000$8.98$4,490,000.002,464,195View SEC Filing  
11/7/2016Joseph K BelanoffCEOSell500,000$8.31$4,155,000.002,257,728View SEC Filing  
5/10/2016G Leonard Baker JrDirectorBuy100,000$4.88$488,000.00721,038View SEC Filing  
1/6/2016James N WilsonDirectorSell1,188$4.90$5,821.20View SEC Filing  
12/10/2015Daniel BradburyDirectorSell20,000$4.85$97,000.00View SEC Filing  
11/24/2015Daniel BradburyDirectorSell40,000$5.00$200,000.00View SEC Filing  
11/12/2015James N WilsonDirectorSell20,000$4.90$98,000.00View SEC Filing  
11/2/2015Steven LoVPSell12,500$4.00$50,000.0012,500View SEC Filing  
10/13/2015Steven LoVPSell53,033$3.82$202,586.06View SEC Filing  
10/7/2015Steven LoVPSell5,300$4.00$21,200.0053,033View SEC Filing  
10/6/2015Steven LoVPSell50,000$3.76$188,000.0058,333View SEC Filing  
9/16/2015Daniel BradburyDirectorSell20,000$4.96$99,200.00View SEC Filing  
9/1/2015James N WilsonDirectorSell10,000$4.90$49,000.00View SEC Filing  
8/27/2015Daniel BradburyDirectorSell20,000$4.76$95,200.00View SEC Filing  
7/21/2015Daniel BradburyDirectorSell10,000$4.98$49,800.00View SEC Filing  
7/20/2015Daniel BradburyDirectorSell10,000$5.32$53,200.00View SEC Filing  
7/8/2015David L MahoneyDirectorSell33,828$5.74$194,172.72View SEC Filing  
7/1/2015James N WilsonDirectorSell10,000$6.06$60,600.00View SEC Filing  
6/24/2015Daniel BradburyDirectorSell20,000$6.75$135,000.00View SEC Filing  
6/23/2015Daniel BradburyDirectorSell10,000$6.92$69,200.00View SEC Filing  
6/2/2015James N WilsonDirectorSell10,000$6.13$61,300.00View SEC Filing  
3/24/2015Patrick G EnrightDirectorSell1,089,745$5.75$6,266,033.75View SEC Filing  
3/19/2015Joseph C Cook JrDirectorSell77,200$5.22$402,984.00View SEC Filing  
6/11/2014G Leonard Baker JrDirectorBuy103,386$2.32$239,855.52View SEC Filing  
5/13/2014Joseph Cook, Jr.DirectorBuy100,000$1.84$184,000.002,040,826View SEC Filing  
5/12/2014Daniel BradburyDirectorBuy138,925$1.80$250,065.00View SEC Filing  
5/9/2014G Leonard Baker, Jr.DirectorBuy100,000$1.84$184,000.00578,389View SEC Filing  
5/2/2014Longitude Venture Partners L.PDirectorSell250,000$4.11$1,027,500.00View SEC Filing  
4/1/2014Patrick EnrightDirectorSell250,000$4.28$1,070,000.00View SEC Filing  
3/7/2014Longitude Venture Partners L.PDirectorSell250,000$4.00$1,000,000.00View SEC Filing  
3/14/2013Joseph L TurnerDirectorBuy10,000$2.01$20,100.00View SEC Filing  
12/5/2012G Leonard Baker JrDirectorBuy87,131$1.46$127,211.26View SEC Filing  
11/23/2012Daniel BradburyDirectorBuy179,000$1.39$248,810.00View SEC Filing  
11/7/2012G Leonard Baker JrDirectorBuy300,000$1.83$549,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corcept Therapeutics (NASDAQ CORT) News Headlines

Source:
DateHeadline
Corcept Therapeutics (CORT) Scheduled to Post Quarterly Earnings on ThursdayCorcept Therapeutics (CORT) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - February 16 at 8:14 PM
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference CallCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results, Provide Corporate Update, Host Conference Call
finance.yahoo.com - February 15 at 5:16 PM
Why Corcept Therapeutics Stock Gained 27.4% in JanuaryWhy Corcept Therapeutics Stock Gained 27.4% in January
www.fool.com - February 13 at 6:19 PM
Corcept Therapeutics - Speculative Buy After Fears On Generic Competition - Seeking AlphaCorcept Therapeutics - Speculative Buy After Fears On Generic Competition - Seeking Alpha
seekingalpha.com - February 12 at 7:07 AM
Insider Selling: Corcept Therapeutics Incorporated (CORT) Insider Sells 8,000 Shares of StockInsider Selling: Corcept Therapeutics Incorporated (CORT) Insider Sells 8,000 Shares of Stock
www.americanbankingnews.com - February 9 at 9:26 PM
CORT Crosses Below Key Moving Average LevelCORT Crosses Below Key Moving Average Level
www.nasdaq.com - February 8 at 3:27 PM
Corcept Therapeutics Incorporated (CORT) Receives Average Recommendation of "Buy" from AnalystsCorcept Therapeutics Incorporated (CORT) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 6 at 5:24 PM
Xtandi Prospers, One Down, One To Go For AMAG, Theres Reason For CORTs FallXtandi Prospers, One Down, One To Go For AMAG, There's Reason For CORT's Fall
www.nasdaq.com - February 6 at 6:52 AM
Corcept Therapeutics (CORT) Receives Letter Advising That Teva (TEVA) Submitted ANDA for Generic KORLYMCorcept Therapeutics (CORT) Receives Letter Advising That Teva (TEVA) Submitted ANDA for Generic KORLYM
www.streetinsider.com - February 6 at 6:52 AM
Why Corcept Therapeutics Incorporated Stock Is Getting Clobbered TodayWhy Corcept Therapeutics Incorporated Stock Is Getting Clobbered Today
www.fool.com - February 5 at 4:46 PM
Corcept Therapeutics (CORT) Price Target Lowered to $20.00 at Stifel NicolausCorcept Therapeutics (CORT) Price Target Lowered to $20.00 at Stifel Nicolaus
www.americanbankingnews.com - February 5 at 4:24 PM
Mid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops ExpectationsMid-Morning Market Update: Markets Open Lower; Bristol-Myers Profit Tops Expectations
www.benzinga.com - February 5 at 3:26 PM
Corcepts stock tumbles after Teva submits NDA for generic KorlymCorcept's stock tumbles after Teva submits NDA for generic Korlym
finance.yahoo.com - February 5 at 3:26 PM
Corcept Therapeutics (CORT) FY18 Revenue Guidance Tops Views - StreetInsider.comCorcept Therapeutics (CORT) FY18 Revenue Guidance Tops Views - StreetInsider.com
www.streetinsider.com - February 1 at 3:27 PM
Biotech Roundup: Who's Popping On Drug, Merger, Earnings News?Biotech Roundup: Who's Popping On Drug, Merger, Earnings News?
finance.yahoo.com - February 1 at 3:27 PM
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue GuidanceCorcept Therapeutics Announces Fourth Quarter and Full-Year 2017 Preliminary Selected Financial Results; Provides 2018 Revenue Guidance
finance.yahoo.com - February 1 at 3:27 PM
Aquinox Pharmaceuticals (AQXP) and Corcept Therapeutics (CORT) Critical AnalysisAquinox Pharmaceuticals (AQXP) and Corcept Therapeutics (CORT) Critical Analysis
www.americanbankingnews.com - January 29 at 5:14 PM
Short Interest in Corcept Therapeutics Incorporated (CORT) Decreases By 6.0%Short Interest in Corcept Therapeutics Incorporated (CORT) Decreases By 6.0%
www.americanbankingnews.com - January 27 at 3:16 AM
Reviewing Impax Laboratories (IPXL) & Corcept Therapeutics (CORT)Reviewing Impax Laboratories (IPXL) & Corcept Therapeutics (CORT)
www.americanbankingnews.com - January 18 at 9:10 AM
Corcept Therapeutics (CORT) Upgraded to "Buy" by BidaskClubCorcept Therapeutics (CORT) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - January 15 at 12:44 AM
Corcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by BrokeragesCorcept Therapeutics Incorporated (CORT) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 12 at 5:54 PM
Corcept Therapeutics Incorporated (CORT) Sees Large Increase in Short InterestCorcept Therapeutics Incorporated (CORT) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 12 at 2:38 AM
Corcept Therapeutics Incorporated (CORT) Insider Robert S. Fishman Sells 8,000 SharesCorcept Therapeutics Incorporated (CORT) Insider Robert S. Fishman Sells 8,000 Shares
www.americanbankingnews.com - January 10 at 8:00 PM
Immune Pharmaceuticals (IMNP) vs. Corcept Therapeutics (CORT) Head to Head SurveyImmune Pharmaceuticals (IMNP) vs. Corcept Therapeutics (CORT) Head to Head Survey
www.americanbankingnews.com - January 6 at 11:36 PM
ETFs with exposure to Corcept Therapeutics, Inc. : December 29, 2017ETFs with exposure to Corcept Therapeutics, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 5:17 PM
Why is Corcept's Stock Up More Than 150% So Far This Year?Why is Corcept's Stock Up More Than 150% So Far This Year?
finance.yahoo.com - December 29 at 11:06 AM
Corcept Therapeutics (CORT) Cut to Hold at BidaskClubCorcept Therapeutics (CORT) Cut to Hold at BidaskClub
www.americanbankingnews.com - December 24 at 9:32 AM
Strength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8% - NasdaqStrength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8% - Nasdaq
www.nasdaq.com - December 24 at 12:51 AM
Corcept Therapeutics Shows Rising Price Performance With Jump To 95 RS RatingCorcept Therapeutics Shows Rising Price Performance With Jump To 95 RS Rating
finance.yahoo.com - December 22 at 9:22 PM
Jim Cramer Gives His Opinion On Alphabet, Switch, And MoreJim Cramer Gives His Opinion On Alphabet, Switch, And More
www.benzinga.com - December 22 at 9:36 AM
Jazz Submits NDA to FDA for JZP-110 to Cure Sleep DisorderJazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder
finance.yahoo.com - December 22 at 9:36 AM
Strength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8%Strength Seen in Corcept Therapeutics (CORT): Stock Soars 10.8%
finance.yahoo.com - December 22 at 9:36 AM
Why Corcept Therapeutics Shares Climbed 10.8% TodayWhy Corcept Therapeutics Shares Climbed 10.8% Today
www.fool.com - December 21 at 5:23 PM
This Biotech Stock Launched After Joining The S&P 600 SmallCapThis Biotech Stock Launched After Joining The S&P 600 SmallCap
finance.yahoo.com - December 21 at 5:21 PM
Corcept Therapeutics Incorporated (CORT) Receives Consensus Rating of "Buy" from BrokeragesCorcept Therapeutics Incorporated (CORT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 18 at 7:58 PM
Traders Purchase Large Volume of Corcept Therapeutics Put Options (CORT)Traders Purchase Large Volume of Corcept Therapeutics Put Options (CORT)
www.americanbankingnews.com - December 18 at 3:10 AM
Corcept Therapeutics (CORT) Upgraded at BidaskClubCorcept Therapeutics (CORT) Upgraded at BidaskClub
www.americanbankingnews.com - December 17 at 8:32 AM
ETFs with exposure to Corcept Therapeutics, Inc. : December 13, 2017ETFs with exposure to Corcept Therapeutics, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:30 PM
Corcept Therapeutics Incorporated (CORT) Short Interest UpdateCorcept Therapeutics Incorporated (CORT) Short Interest Update
www.americanbankingnews.com - December 13 at 1:10 AM
Robert S. Fishman Sells 8,000 Shares of Corcept Therapeutics Incorporated (CORT) StockRobert S. Fishman Sells 8,000 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - December 12 at 6:06 PM
Head-To-Head Comparison: Corcept Therapeutics (CORT) & SciClone Pharmaceuticals (SCLN)Head-To-Head Comparison: Corcept Therapeutics (CORT) & SciClone Pharmaceuticals (SCLN)
www.americanbankingnews.com - December 12 at 6:00 AM
Corcept Therapeutics (CORT) Downgraded by BidaskClub to "Hold"Corcept Therapeutics (CORT) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - December 9 at 7:16 PM
2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma - Benzinga2 Reasons Why Cantor Fitzgerald Is Bullish on Strongbridge Biopharma - Benzinga
www.benzinga.com - December 6 at 5:22 PM
AstraZenecas Tagrisso Label Expansion Filing Accepted by EMA - NasdaqAstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA - Nasdaq
www.nasdaq.com - November 29 at 5:40 PM
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDAGlaxo Submits NDA for Anti Relapse Malaria Medicine to FDA
www.zacks.com - November 29 at 9:35 AM
Contrasting Marinus Pharmaceuticals (MRNS) and Corcept Therapeutics (CORT)Contrasting Marinus Pharmaceuticals (MRNS) and Corcept Therapeutics (CORT)
www.americanbankingnews.com - November 27 at 12:15 PM
Corcept Therapeutics Incorporated (CORT) Given Average Recommendation of "Buy" by AnalystsCorcept Therapeutics Incorporated (CORT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 23 at 9:36 PM
Can Valeant (VRX) Turn Around on Rebuilding Initiatives?Can Valeant (VRX) Turn Around on Rebuilding Initiatives?
finance.yahoo.com - November 21 at 5:35 PM
Roche Reports Positive Data From Tecentriq Combination Study ... - NasdaqRoche Reports Positive Data From Tecentriq Combination Study ... - Nasdaq
www.nasdaq.com - November 20 at 11:30 PM
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 20, 2017Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : November 20, 2017
finance.yahoo.com - November 20 at 6:29 PM

SEC Filings

Corcept Therapeutics (NASDAQ:CORT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Corcept Therapeutics (NASDAQ:CORT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Corcept Therapeutics (NASDAQ CORT) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.